Coherus Oncology regains Nasdaq compliance after bid price shortfall

Coherus Oncology, Inc.

On June 30, 2025, Coherus received a Nasdaq deficiency notice for bid price below $1.00 for 30 consecutive business days.
Company had 180 days, until December 29, 2025, to regain compliance.
On September 5, 2025, Nasdaq confirmed Coherus's closing price was $1.00 or greater for the requisite period.
Company is now in full compliance with all Nasdaq continued listing standards; matter is closed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.